摘要
目的比较吉西他滨+顺铂+重组人血管内皮抑制素(GPE)方案与吉西他滨+顺铂(GP)方案在非小细胞肺癌(NSCLC)患者治疗中的有效性和安全性。方法采用Cochrane系统评价方法,检索Cochrane图书馆、PubMed、Embase、CNKI、万方等数据库中有关GPE方案与GP方案治疗NSCLC的文献,用RevMan5.1软件比较以上2种方案的有效性和安全性。结果共纳入文献10篇,分析结果表明:GPE方案在总有效率(RR)和疾病控制率(DCR)上均优于GP方案(分别为P<0.000 01;P<0.000 1);这2种方案在血小板减少和恶心呕吐的发生率上无统计学意义(P值分别0.07和0.08);但是,GP方案的白细胞减少发生率高于GPE方案(P>0.003);而GPE方案的心脏毒性发生率高于GP方案(P=0.02)。结论 GPE方案治疗NSCLC的总体效果比GP方案好,可降低白细胞减少的发生率,但也存在一定的心脏毒性。由于纳入的文献质量整体评分不高,上述结论仍需要设计良好的大型临床随机对照试验来验证。
Objective To assess the effect and safety of rh-endostatin plus the combination of gemcitabine and cisplatin（GPE） vs GP regimen alone for non-small cell lung cancer.Methods We systematically retrieved the Cochrane library,PubMed,Embase,CNKI,Wanfang data,etc.RevMan5.1 software was used to compare the effect and safety of the two regimens.Results Ten literatures were included.Meta-analysis suggested that GPE regimen had some advantage over GP regimen on both the response rate（RR） and the disease control rate（DCR）（P0.000 01,P0.000 1）.The leucopenia rate of GP regimen was higher than that of GPE regimen（P=0.003）.Both the thrombocytopenia rate and the nausea and vomiting rate were not statistically significant（P： 0.07 and 0.08）,while the cardiotoxic rate of GPE regimen was higher than that of GP regimen（P=0.02）.Conclusion The GPE regimen is superior to GP regimen for NSCLC in terms of effect and safety,especially in leucopenia,but the GPE regimen is cardiotoxic in some way.In view of the limitation of the included literatures,these conclusions need to be supported by large clinical trials.
出处
《中南药学》
CAS
2012年第10期781-787,共7页
Central South Pharmacy
基金
国家自然科学基金(编号:81173028)
